Adalimumab is an anti-inflammatory medication usually prescribed for treating Crohn's disease, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, moderate to severe hidradenitis suppurativa, moderate to se...英国华人论坛
The LATAM adalimumab market is expected to climb up to US$1.18 bn in 2023. This market was valued at US$994.8 mn in 2014 and, according to a research report, is expanding at a CAGR of 0.4% within a forecast period from 2015 to 2023. The rese...英国华人论坛
Adalimumab is a biologic TNF inhibiting anti-inflammatory medication which is a patented medicine of Abbott Biotechnology Ltd. Jochen G. Salfeld et al invented the product and trade names for the product are Exemptia and Humira. Humira stand...英国华人论坛
This report on LATAM Adalimumab market analyzes the current and future prospects of the adalimumab sales pertaining to Latin American countries. The stakeholders of this report include companies engaged in production and commercialization of...英国华人论坛